Frederic Picard
Founder & CEO
About us
Regenerative medicine without permanent implants
Prometheus Regeneration is dedicated to transforming regenerative medicine through graphene-enhanced 3D bioprinting. We believe the future of healthcare lies in giving the body the tools to heal itself, without the limitations of permanent synthetic implants, loosening and repeat revision surgery.
Our BioReJen® platform starts with bone: a staged path from bone void filling to revision adjuncts and, ultimately, regenerative load-bearing implants.
Graphene-enhanced
scaffolds 3D bioprinting Regenerative
medicine
scaffolds 3D bioprinting Regenerative
medicine
BioReJen® sits where 3D bioprinting, graphene-enhanced scaffolds and regenerative medicine meet, a combination few teams can bring together in one place.
Science-based clinical expertise
Regenerative-medicine research and bioprinting, guided by hands-on surgical experience.
Will Shu
CSO
Jason King
CTO
Darren Lee
COO
Gilles Thieffry
Acting as General Counsel
Michael Hickman
Director
Rachael Pirie
Biomedical Engineer
Ian MacKenzie
Biomedical Engineer
Jane McGregor
PA & Company Secretary
Milestones so far
- 2018
Company founded
Founded in Glasgow to move orthopaedics from joint replacement to biological regeneration.
- 2018
Scientific breakthrough
Landmark publication on 3D bioactive composite scaffolds for bone tissue engineering (Bioactive Materials, 2018). Read the paper (opens in a new tab)
- 2019
IP foundation
Built a defensible patent portfolio, with novelty confirmed by independent searches.
- 2020
Innovate UK Smart grant
Won Innovate UK’s flagship award for disruptive R&D, using graphene to generate tissues for joint-replacement components. See the competition results (PDF) (opens in a new tab)
- 2023
Biomedical Catalyst grant
Innovate UK’s flagship health-innovation award, for developing bioactive graphene-based scaffolds for tissue repair. See the project at Strathclyde (opens in a new tab)
- 2024
MedTech & Diagnostics GBIP, Singapore
Selected for the Global Business Innovation Programme (GBIP) for MedTech & Diagnostics in Singapore. See the programme (opens in a new tab)
- 2025
Preclinical validation
Successful animal studies, with a second in vivo study underway. See the NAMSA study →
- Now
Seed investment
Secured to move from R&D to commercial development.
- Future
Commercialisation
Bone void filler → revision adjuncts → 3D-bioprinted joint replacement.
Get in touch
On request, we share our investor presentation and the materials relevant to your enquiry with qualified parties.